A randomised trial of nonselective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.

 

Trial Summary:

To determine whether lymphadenectomy, used to restrict adjuvant therapy (other than vaginal brachytherapy) to node positive women, results in a non-inferior survival as compared to adjuvant therapy given to all women with high risk apparent stage I endometrial cancer.

Supported By:

University College London

Eligibility:

Women with histologically confirmed high risk apparent FIGO stage I endometrial cancer based on diagnostic endometrial sampling OR hysterectomy and BSO specimen if randomisation occurring after hysterectomy and BSO:
• FIGO grade 3 endometrioid or mucinous
• High grade serous, clear cell, undifferentiated or dedifferentiated carcinoma or mixed cell adenocarcinoma or carcinosarcoma

Registration ID:

ACTRN12617000714381

Participation:

UK, Australia

Australian Lead Group:

ANZGOG

Status:

Recruiting

Activation Date:

28.11.2017

Chairs:

A/Prof Alison Brand

Contact:

statec.study@sydney.edu.au